PBM
CRVS icon

Propel Bio Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Propel Bio Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Sell
70,380
-15,411
-18% -$214K 0.55% 28
2026
Q1 		$1.25M Buy
+85,791
New +$1.37M 0.79% 34

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Propel Bio Management's CRVS Position: Q2 2026 in Review

Propel Bio Management reduced its Corvus Pharmaceuticals (CRVS) stake by 18% in Q2 2026, selling an estimated $214K and leaving 70,380 shares worth $1.05M. The position accounts for 0.55% of the portfolio, ranked #28.

Propel Bio Management first reported a position in CRVS in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.25M in Q1 2026. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Propel Bio Management held 70,380 shares of Corvus Pharmaceuticals worth $1.05M as of Q2 2026.
  • Propel Bio Management sold 15,411 Corvus Pharmaceuticals shares in Q2 2026, an estimated $214K.
  • Corvus Pharmaceuticals made up 0.55% of Propel Bio Management's portfolio in Q2 2026, its #28 holding.
  • Propel Bio Management first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Propel Bio Management's Corvus Pharmaceuticals position peaked at $1.25M in Q1 2026.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.